Transgenomic, Inc. has entered an agreement with Raptor Pharmaceuticals, Inc. to provide genetic testing services for Raptor’s clinical trial evaluating RP103 as a potential treatment for Leigh syndrome and other inherited mitochondrial disorders. Leigh syndrome is a severe neurological disorder characterized by progressive loss of mental and movement abilities and typically results in death within a few years, usually due to respiratory failure.   “We look forward to working with Raptor and the...